Results 1 to 10 of about 554,589 (315)

Predictors of dopamine agonist resistance in prolactinoma patients. [PDF]

open access: yesBMC Endocr Disord, 2020
Background Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we
Vermeulen E   +6 more
europepmc   +3 more sources

Dopamine agonist withdrawal syndrome associated factors: A retrospective chart review. [PDF]

open access: yesClin Park Relat Disord, 2022
Dopamine agonist withdrawal syndrome (DAWS) has been introduced to describe the constellation of symptoms resulting from reduction or suspension of dopamine agonist medications.
Garcia X   +4 more
europepmc   +2 more sources

Dopamine agonist monotherapy utilization in patients with Parkinson's disease. [PDF]

open access: yesClin Park Relat Disord, 2023
Objectives: To characterize patients with Parkinson’s disease (PD) who initiated dopamine agonist (DA) monotherapy, describe medication utilization and provider types, and estimate medication adherence and discontinuation rates.
Frazer M, Arcona S, Le L, Sasane R.
europepmc   +2 more sources

Irreversible extreme freezing of gait after dopamine agonist withdrawal. [PDF]

open access: yesClin Case Rep, 2021
Dopamine agonist withdrawal can cause freezing of gait in PD patients.
Salari M   +4 more
europepmc   +2 more sources

The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease.

open access: yesPLoS ONE, 2015
The progressive degeneration of the dopamine neurons of the pars compacta of substantia nigra and the consequent loss of the dopamine innervation of the striatum leads to the impairment of motor behavior in Parkinson's disease.
Luis F Razgado-Hernandez   +8 more
doaj   +2 more sources

Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors

open access: yesParkinson's Disease, 2021
Objective. To investigate the use of dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors in the Norwegian population, between 1 July 2006 and 31 December 2016.
Caroline D. Binde   +2 more
doaj   +1 more source

Dopamine inhibits mitochondrial motility in hippocampal neurons. [PDF]

open access: yesPLoS ONE, 2008
The trafficking of mitochondria within neurons is a highly regulated process. In an earlier study, we found that serotonin (5-HT), acting through the 5-HT1A receptor subtype, promotes axonal transport of mitochondria in cultured hippocampal neurons by ...
Sigeng Chen   +2 more
doaj   +1 more source

Adsorption properties of dopamine derivatives using carbon nanotubes: A first-principles study [PDF]

open access: yesApplied Surface Science, Volume 501, 31 January 2020, 144249, 2020
Detecting dopamine is of great biological importance because the molecule plays many roles in the human body. For instance, the lack of dopamine release is the cause of Parkinson's disease. Although many researchers have carried out experiments on dopamine detection using carbon nanotubes (CNTs), there are only a few theoretical studies on this topic ...
arxiv   +1 more source

Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. [PDF]

open access: yesPLoS ONE, 2012
Dopamine D(2) receptor partial agonist antipsychotic drugs can modulate dopaminergic neurotransmission as functional agonists or functional antagonists.
Hiroshi Ito   +8 more
doaj   +1 more source

Management of Dopamine Agonist-Resistant Prolactinoma

open access: yesNeuroendocrinology, 2019
Dopamine agonists are usually very effective in the treatment of prolactinomas. Nonetheless, a subset of individuals does not respond satisfactorily to these agents, and this resistance is characterized by failure to achieve normoprolactinemia and a 30 ...
D. Maiter
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy